ALLARITY THERAPEUTICS INC (ALLR)

Company Profile

Allarity Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2021-12-21. Allarity Therapeutics, Inc. is a clinical-stage, precision medicine pharmaceutical company. The company is advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its clinical program includes three anti-cancer assets in mid-stage clinical development and one anti-cancer asset in early-stage clinical development. Its programs and partnerships leverage its Drug Response Predictor technology to refine patient selection and improve clinical outcomes. The company is focused on clinical development of three programs: dovitinib in combination with stenoparib for the second-line or later treatment of metastatic ovarian cancer; stenoparib as a monotherapy for ovarian cancer, and IXEMPRA as a monotherapy for metastatic breast cancer. Its dovitinib is a selective inhibitor of several classes of tyrosine kinases, including FGFR and VEGFR. Its IXEMPRA is a selective microtubule inhibitor, which has been shown to interfere with cancer cell division, to cell death.

Company Info

ALLARITY THERAPEUTICS INC

24 School St., 2Nd Floor

Boston MASSACHUSETTS

P: 14014264664

Employees: 9

Website: https://allarity.com/